Format

Send to

Choose Destination
FEBS J. 2015 Mar;282(5):834-849. doi: 10.1111/febs.13188. Epub 2015 Jan 23.

Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

Author information

1
Division of Developmental Immunology, Biocenter, Medical University Innsbruck, Austria.
2
Laboratory for Immunological and Molecular Cancer Research, Third Medical Department, Paracelsus Medical University, Salzburg, Austria.
#
Contributed equally

Abstract

Cell survival depends on the maintenance of mitochondrial integrity controlled by a well-balanced interplay between anti- and pro-apoptotic B cell lymphoma 2 (Bcl2) family members. Given their frequent deregulation in human pathologies, including autoimmunity and cancer, significant research efforts have increased our molecular understanding of how Bcl2 proteins control cell death. This has fostered the development of small non-peptidic compounds, so-called BH3-mimetics, that show excellent prospects of passing clinical trials and entering daily use for targeted therapy. Possible limitations in clinical application may, to a certain degree, be predicted from loss-of-function phenotypes gathered from studies using gene-modified mice that we attempt to summarize and discuss in this context.

KEYWORDS:

Bcl-2 family; apoptosis; cancer; mouse models; targeted therapy

PMID:
25559680
PMCID:
PMC4562365
DOI:
10.1111/febs.13188
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center